AI SummaryThis article discusses the poor outcomes of basal/squamous and mixed subtype bladder cancers after neoadjuvant chemotherapy in the VESPER trial. It highlights the need for predictive biomarkers for response or chemoresistance in muscle-invasive bladder cancer, with gene expression-based subtypes being considered as potential markers. The response of the basal subtype to chemotherapy is a… Continue reading Basal/squamous and Mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial
Tag: Chemotherapy and Cancer Pharmacology
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
AI SummaryThe article discusses the use of circulating-tumor DNA (ctDNA)-based molecular residual disease (MRD) detection in patients with colorectal liver metastases (CLM). The study aims to explore the survival benefit of adjuvant chemotherapy (ACT) in this patient population after surgical resection. This research could potentially provide valuable insights into risk-stratification and treatment options for individuals… Continue reading Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Dorsal root ganglion inflammation by oxaliplatin toxicity: DPEP1 as possible target for peripheral neuropathy prevention
Peripheral neuropathy (PN) constitutes a dose-limiting side effect of oxaliplatin chemotherapy that often compromises the efficacy of antineoplastic treatments. Sensory neurons damage in dorsal root ganglia (D…
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
AI SummaryIn the phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial, Niraparib first-line maintenance therapy showed significant improvement in progression-free survival (PFS) for patients with newly diagnosed advanced ovarian cancer (aOC) who responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. The final overall survival (OS) results are reported, indicating the potential benefits of this treatment… Continue reading Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
AI SummaryThis study focuses on the use of pembrolizumab in combination with adjuvant chemotherapy in patients with newly diagnosed, high-risk endometrial cancer. The research aims to evaluate the potential benefits of this treatment approach in patients without residual macroscopic disease post-surgery. Previous findings show that pembrolizumab plus chemotherapy can be beneficial for advanced endometrial cancer,… Continue reading ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer
AI SummaryThis article discusses the effectiveness of an antibody-drug conjugate called trastuzumab deruxtecan (T-DXd) against brain metastases in patients with advanced HER2-positive breast cancer. The drug delivers chemotherapy directly to tumors and has shown impressive activity against hard-to-reach cancer cells. Results from an international clinical trial support the benefits of T-DXd in treating these patients.A… Continue reading Antibody-drug conjugate found effective against brain metastases in patients with HER2-positive breast cancer
Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer
AI SummaryThe article discusses a study that highlights tumor-induced B cell changes in the blood and bone marrow of triple negative breast cancer patients. The research identifies two distinct patterns of B cell abnormalities that could potentially be used as blood biomarkers to predict the response to standard chemotherapy and immunotherapy. This discovery could aid… Continue reading Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer
[Articles] Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
AI SummaryThe article discusses a phase 2 trial of combining sintilimab and bevacizumab in patients with relapsed or persistent ovarian clear cell carcinoma. The combination showed promising anti-tumour activity and manageable safety. Larger randomized trials are needed to compare this regimen with standard chemotherapy.Sintilimab in combination with bevacizumab showed promising anti-tumour activity and manageable safety… Continue reading [Articles] Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
[Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
AI SummaryThe article discusses the results of a phase 2 trial (MOLTO) on combining atezolizumab, venetoclax, and obinutuzumab in treating Richter transformation diffuse large B-cell lymphoma (DLBCL-RT). The study indicates that this chemotherapy-free regimen is effective and safe, potentially offering a new first-line treatment option for patients with DLBCL-RT.The atezolizumab, venetoclax, and obinutuzumab triplet combination… Continue reading [Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer
AI SummaryThis study explores the role of intratumoral CXCL13+ CD160+ CD8+ T cells in promoting the formation of tertiary lymphoid structures (TLSs) to enhance the efficacy of immunotherapy in advanced gastric cancer. The researchers found that responders to immunochemotherapy had higher levels of TLSs and CXCL13+ CD160+ CD8+ T cells, which led to better outcomes.… Continue reading Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer